表紙
市場調查報告書

遺傳基因檢驗的全球市場:2020年∼2024年

Genetic Testing Market by Product, End-user, Application, and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 276812
出版日期 內容資訊 英文 171 Pages
訂單完成後即時交付
價格
遺傳基因檢驗的全球市場:2020年∼2024年 Genetic Testing Market by Product, End-user, Application, and Geography - Forecast and Analysis 2020-2024
出版日期: 2019年11月14日內容資訊: 英文 171 Pages
簡介

全球遺傳基因檢驗市場上,遺傳基因疾病及障礙的盛行率上升,先進的遺傳基因檢驗產品的認證增加,遺傳基因檢驗的成本降低使受檢變得容易等成為成長促進因素,在預測期間內預計以12%以上的年複合成長率擴大。但,全球遺傳基因檢驗和研究相關各式法規,產品回收相關問題,及熟練的遺傳專家的不足等要素,可能妨礙在預測期間內遺傳基因檢驗產業的成長。

本報告提供全球遺傳基因檢驗市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析
  • 價值鏈分析

第4章 市場規模

  • 市場定義
  • 市場規模(2019年)
  • 市場規模及預測(2019年∼2024年)
  • 市場預測

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2019年∼2024年)
  • 設備
  • 消耗品
  • 市場機會:各產品

第7章 市場區隔:各終端用戶

  • 臨床診斷研究所
  • 醫院
  • 生物醫藥品企業及研究中心

第8章 市場區隔:各應用領域

  • 預測及診斷試驗
  • 產前,新生兒及胚胎著床前檢驗
  • 藥理基因檢驗
  • 法醫學,血緣關係,祖先檢驗

第9章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2019年∼2024年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第10章 客戶形勢

第11章 決策架構

第12章 成長要素與課題

  • 市場成長要素
  • 市場課題

第13章 市場趨勢

  • 次世代定序的進步
  • 早期的病診斷中直銷的遺傳基因檢驗採用的擴大
  • 藥物不良事件降低的藥物遺傳學的檢驗採用的擴大

第14章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第15章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • bioMerieux SA
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina Inc.
  • Myriad Genetics Inc.
  • QIAGEN NV
  • Quest Diagnostics Inc.
  • Thermo Fisher Scientific Inc.

第16章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第17章 關於TECHNAVIO

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR40152

About this market

Technavio's genetic testing market analysis considers sales from both equipment and consumable products. Our study also finds the sales of genetic testing in Asia, Europe, North America, and ROW. In 2019, the equipment segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing workload for performing high-throughput tests in clinical diagnostic facilities will play a significant role in the equipment segment to maintain its market position. Also, our global genetic testing market report looks at factors such as rising prevalence of genetic diseases and disorders, rising approval of advanced genetic testing products, and increasing affordability due to reduction in cost of genetic testing. However, varying regulations on genetic testing and research globally, issues related to product recalls, and lack of trained genetic professionals may hamper the growth of the genetic testing industry over the forecast period.

Overview

Rising approval of advanced genetic testing products

Commercial applications of genetic screening in human health management and the advent of whole genome sequencing have allowed vendors to offer a variety of innovative products in the global genetic testing market. The use of advanced technologies such as pharmacogenomics and companion diagnostics has helped vendors in assuring the safety of their products. Furthermore, the deployment of rapid and simplified technologies in genetic testing offers several benefits including the reduction in turnaround time, optimum resource use, and accuracy in genetic diagnosis. Thus, the rising approval of advanced genetic testing products will lead to the expansion of the global genetic testing market at a CAGR of over 12% during the forecast period.

Growing adoption of pharmacogenetic testing in reducing adverse drug events

The growing approval of new drug molecules and the rising demand for targeted therapies and personalized medicines have increased the adoption of pharmacogenomic testing by pharmaceutical companies. Pharmacogenomic testing combines the principles of pharmacology and genomics to study the response of an individual to any specific drug. The study of drug-specific responses allows pharmaceutical companies to prevent adverse drug incidence and ensure drug safety and performance during pre and post commercial stages. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global genetic testing market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of several major players, the global genetic testing market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading genetic testing manufacturers, that include Abbott Laboratories, Agilent Technologies Inc., bioMerieux SA, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Myriad Genetics Inc., QIAGEN NV, Quest Diagnostics Inc., and Thermo Fisher Scientific Inc.

Also, the genetic testing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value Chain Analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market Outlook

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Equipment - Market size and forecast 2019-2024
  • Consumables - Market size and forecast 2019-2024
  • Market opportunity by product

PART 07: MARKET SEGMENTATION BY END-USER

  • Clinical diagnostics laboratories
  • Hospitals
  • Biopharmaceutical companies and research centers
  • PART 08: MARKET SEGMENTATION BY APPLICATION
  • Predictive and diagnostic testing
  • Prenatal, newborn and preimplantation testing
  • Pharmacogenomic testing
  • Forensic, relationship and ancestry testing

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 10: CUSTOMER LANDSCAPE

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Advancements in next-generation sequencing
  • Growing adoption of direct-to-consumer genetic tests in early
  • disease diagnosis
  • Growing adoption of pharmacogenetic testing in reducing adverse
  • drug events

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • bioMerieux SA
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina Inc.
  • Myriad Genetics Inc.
  • QIAGEN NV
  • Quest Diagnostics Inc.
  • Thermo Fisher Scientific Inc.

PART 16: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 17: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Global healthcare market
  • Exhibit 02: Segments of global healthcare market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Vendor offerings
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Product - Market share 2019-2024 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Equipment - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 21: Equipment - Year-over-year growth 2020-2024 (%)
  • Exhibit 22: Consumables - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 23: Consumables - Year-over-year growth 2020-2024 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Global genetic testing market segmentation by end-user 2019 (% share)
  • Exhibit 26: Global genetic testing market segmentation by application 2019 (% share)
  • Exhibit 27: Market share by geography 2019-2024 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 31: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 33: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 35: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 36: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: Customer landscape
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: Abbott Laboratories - Vendor overview
  • Exhibit 47: Abbott Laboratories - Product segments
  • Exhibit 48: Abbott Laboratories - Organizational developments
  • Exhibit 49: Abbott Laboratories - Geographic focus
  • Exhibit 50: Abbott Laboratories - Segment focus
  • Exhibit 51: Abbott Laboratories - Key offerings
  • Exhibit 52: Agilent Technologies Inc. - Vendor overview
  • Exhibit 53: Agilent Technologies Inc. - Business segments
  • Exhibit 54: Agilent Technologies Inc. - Organizational developments
  • Exhibit 55: Agilent Technologies Inc. - Geographic focus
  • Exhibit 56: Agilent Technologies Inc. - Segment focus
  • Exhibit 57: Agilent Technologies Inc. - Key offerings
  • Exhibit 58: bioMerieux SA - Vendor overview
  • Exhibit 59: bioMerieux SA - Business segments
  • Exhibit 60: bioMerieux SA - Organizational developments
  • Exhibit 61: bioMerieux SA - Geographic focus
  • Exhibit 62: bioMerieux SA - Key offerings
  • Exhibit 63: Bio-Rad Laboratories Inc. - Vendor overview
  • Exhibit 64: Bio-Rad Laboratories Inc. - Business segments
  • Exhibit 65: Bio-Rad Laboratories Inc. - Organizational developments
  • Exhibit 66: Bio-Rad Laboratories Inc. - Geographic focus
  • Exhibit 67: Bio-Rad Laboratories Inc. - Segment focus
  • Exhibit 68: Bio-Rad Laboratories Inc. - Key offerings
  • Exhibit 69: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 70: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 71: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 72: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 73: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 74: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 75: Illumina Inc. - Vendor overview
  • Exhibit 76: Illumina Inc. - Business segments
  • Exhibit 77: Illumina Inc. - Organizational developments
  • Exhibit 78: Illumina Inc. - Geographic focus
  • Exhibit 79: Illumina Inc. - Segment focus
  • Exhibit 80: Illumina Inc. - Key offerings
  • Exhibit 81: Myriad Genetics Inc. - Vendor overview
  • Exhibit 82: Myriad Genetics Inc. - Business segments
  • Exhibit 83: Myriad Genetics Inc. - Organizational developments
  • Exhibit 84: Myriad Genetics Inc. - Segment focus
  • Exhibit 85: Myriad Genetics Inc. - Key offerings
  • Exhibit 86: QIAGEN NV - Vendor overview
  • Exhibit 87: QIAGEN NV - Product segments
  • Exhibit 88: QIAGEN NV - Organizational developments
  • Exhibit 89: QIAGEN NV - Geographic focus
  • Exhibit 90: QIAGEN NV - Segment focus
  • Exhibit 91: QIAGEN NV - Key offerings
  • Exhibit 92: Quest Diagnostics Inc. - Vendor overview
  • Exhibit 93: Quest Diagnostics Inc. - Business segments
  • Exhibit 94: Quest Diagnostics Inc. - Organizational developments
  • Exhibit 95: Quest Diagnostics Inc. - Segment focus
  • Exhibit 96: Quest Diagnostics Inc. - Key offerings
  • Exhibit 97: Thermo Fisher Scientific Inc. - Vendor overview
  • Exhibit 98: Thermo Fisher Scientific Inc. - Business segments
  • Exhibit 99: Thermo Fisher Scientific Inc. - Organizational developments
  • Exhibit 100: Thermo Fisher Scientific Inc. - Geographic focus
  • Exhibit 101: Thermo Fisher Scientific Inc. - Segment focus
  • Exhibit 102: Thermo Fisher Scientific Inc. - Key offerings
  • Exhibit 103: Validation techniques employed for market sizing
  • Exhibit 104: Definition of market positioning of vendors